Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
With the FDA’s approval of zanubrutinib, CLL / SLL patients have another very strong choice to manage their disease.
In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with none of the more serious abnormal ventricular heart irregularities seen.
WOULD YOU LIKE TO PARTICIPATE IN A DISCUSSION ABOUT CLL / SLL?
WE ARE RECRUITING PARTICIPANTS TO TAKE PART IN A ONE-ON-ONE INTERVIEW ABOUT CLL / SLL
Dr. Susan Leclair has reviewed three abstracts from the 2021 American Society of Hematology Annual Meeting and Exposition, or ASH 2021, on chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients’ responses to vaccines, two on the COVID-19 vaccine, and one on the shingles vaccines.
Many chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients are insured under Medicare – either Original Medicare with a drug plan (Part A, B, and D “a la carte”) or a Medicare Advantage Plan (including Parts A, B, and D Prix fixe). Unfortunately, over the past several years, drug costs have risen significantly for targeted oral anti-cancer drugs.
It is much too early to predict how lisaftoclax will fit into the treatment paradigm for chronic lymphocytic leukemia/small lymphocytic lymphoma. Still, right now, it looks very similar to venetoclax, with the possible advantage of a faster ramp-up to the treatment dose
In this interview, our own Dr. Brian Koffman spoke with Dr. Michael Joyner, an anesthesiologist at the Mayo Clinic in Rochester, MN. They discussed the use of convalescent plasma to treat COVID-19.
In summary, the results of MAJIC will help to inform the selection of time-limited doublet therapy approaches for patients with CLL / SLL and help define the duration of venetoclax in combination with either acalabrutinib or obinutuzumab.
Dr. Javier Pinilla Ibarz and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).
One click to our most popular content.
